On Wednesday,
It identified the substances as stainless steel particles due to a technical failure in the production line of its Spanish supplier, Rovi.
The contamination "does not pose an undue risk to patient safety and it does not adversely affect the benefit/risk profile of the product,"
Kato said at a press conference that the impact of this issue on
He said that alternative supplies have been secured to replace the 1.63 million doses that were shelved when the impurities were detected.
The withdrawn vaccines corresponded to three batches produced at the same time and in the same Rovi plant and were suspended as a precautionary measure after "abnormal substances" were found in some vials of one of the three batches.
The Japanese authorities are also investigating the death of two people who were vaccinated with doses from one of the batches before they were withdrawn to determine whether there was any connection between the deaths and the inoculations.
In their statement on Wednesday, Takeda and
A health ministry spokesperson told EFE on Thursday that possible reactions to
The spokesperson did not wish to comment on whether the Japanese authorities are contemplating imposing some type of sanction on pharmaceutical companies for contamination in vials. EFE
© 2021 EFE News Services (U.S.) Inc., source